Streptococcus Mutans Reduction Early Mother-infant Transmission
27 avril 2021 mis à jour par: Marine Ortiz Magdaleno, Biochemical and Microbiology Laboratory, Faculty of Dentistry, Autonomous University of San Luis Pot
Enhancing Effect of the Application of 1% Chlorhexidine Varnish With Silane Fluoride and Oral Health Promotion on the Streptococcus Mutans Counts Reduction in Pregnant Women and on Early Mother-infant Transmission
Evidence exists on the vertical transmission of Streptococcus mutans from the mother to her children.
This transmission can be prevented by maintaining maternal oral health during pregnancy.
Aperçu de l'étude
Statut
Complété
Les conditions
Description détaillée
The aim of this study was to evaluate the enhancing effect of 1% chlorhexidine varnish together with silane fluoride re-mineralizing varnish and oral health promotion strategy on the reduction of S. mutans counts in saliva of pregnant women and the early mother-infant transmission until the first six months of age of the newborn.
Methods: An open, random clinical trial of parallel groups was performed.
56 pregnant women free of caries were studied prospectively and longitudinally since the third trimester of gestation until 6 months after giving birth, the newborns were also assessed until reaching 6 months of age.
Two groups were formed assigning 28 women to each intervention group.
G-I received 0.1% silane fluoride applied as varnish in each visit.
G-II women's teeth were coated with 0.1% silane fluoride and 1% chlorhexidine.
For the primary culture, CRT Bacteria® system (Ivoclar-Vivadent™) was used for the growth and identification of cariogenic Streptococci.
Identification of S. mutans was performed through PCR.
The DNA of the isolates identified molecularly as S. mutans was used for a second PCR reaction using the arbitrary primer OPA-O2 to determine the homology among the samples of isolated bacteria from the mother-child pair.
Type d'étude
Interventionnel
Inscription (Réel)
58
Phase
- Phase 4
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 45 ans (Adulte)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Femelle
La description
Inclusion Criteria:
- Pregnant women in the third trimester with a normal and healthy pregnancy.
- Ages ranged from 18 to 45 years
- Free of caries (if caries were present, they were treated before enrolling them in the study).
Exclusion Criteria:
-Non-pregnant women
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Pregnant women to whom applied silane fluoride
We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
|
Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
Autres noms:
|
|
Expérimental: Pregnant women to whom applied silane fluoride + 1% chlorhexidine
We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
|
Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
Autres noms:
|
|
Aucune intervention: Children of the pregnant women to whom it was applied silane fluoride
The children not given any intervention, they were only subjected to a microbiological and clinical examination.
|
|
|
Aucune intervention: Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine
The children not given any intervention, they were only subjected to a microbiological and clinical examination.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Caries prevalence assessment in pregnant womens
Délai: Basal measurement, at the beginning of the third trimester of gestation.
|
For this purpose, the Decayed, Missing, and Filled Teeth Index was used to measure the prevalence of caries.
This index is based on in-field clinical examination of individuals by using a probe, mirror and cotton rolls, and simply counts the number of decayed, missing (due to caries only) and restored teeth the number of participants with prevalence of caries will be reported.
|
Basal measurement, at the beginning of the third trimester of gestation.
|
|
Streptococcus mutans levels identified in pregnant womens
Délai: Basal measurement, at the beginning of the third trimester of gestation.
|
In this measurement was identified the S. mutans counts in the saliva of pregnant women after the applications of 1% chlorhexidine varnish together with the application of silane fluoride re-mineralizing varnish or only with the application of silane fluoride, was reported the distribution of cariogenic Streptococcus levels in mothers.
|
Basal measurement, at the beginning of the third trimester of gestation.
|
|
Streptococcus mutans levels identified in pregnant womens
Délai: Three months after the birth of the child.
|
In this measurement was identified the S. mutans counts in the saliva of pregnant women after the applications of 1% chlorhexidine varnish together with the application of silane fluoride re-mineralizing varnish or only with the application of silane fluoride, was reported the distribution of cariogenic Streptococcus levels in mothers.
|
Three months after the birth of the child.
|
|
Streptococcus mutans levels identified in pregnant womens
Délai: Six months after the birth of the child
|
In this measurement was identify the S. mutans counts in the saliva of pregnant women after the applications of 1% chlorhexidine varnish together with the application of silane fluoride re-mineralizing varnish or only with the application of silane fluoride.
Will be reported the distribution of cariogenic Streptococcus levels in mothers.
|
Six months after the birth of the child
|
|
Genotypes of the isolates of S. mutans in pregnant womens.
Délai: Three months after the birth of the child.
|
The genotypes describes an organism's complete set of genes, in this study, was determined the homology among the samples of isolated bacteria from the mother-child pair.
The molecular PCR test was implemented for the identification.
Will be reported the % of S. mutans genotypes isolated from the mothers of both groups to the strains isolated from the newborns.
|
Three months after the birth of the child.
|
|
Streptococcus mutans levels identified in childrens
Délai: Three months after the birth of the child.
|
In this measurement was identified the S. mutans counts in the saliva of the children.
Will be reported the distribution of cariogenic Streptococcus levels in the children.
|
Three months after the birth of the child.
|
|
Streptococcus mutans levels identified in children
Délai: Six months after the birth of the child.
|
In this measurement was identified the S. mutans counts in the saliva of the children.
Will be reported the distribution of cariogenic Streptococcus levels in the children.
|
Six months after the birth of the child.
|
|
Genotypes of the isolates of S. mutans in children.
Délai: Three months after the birth of the child.
|
The genotypes describes an organism's complete set of genes, in this study was determined the homology among the samples of isolated bacteria from the mother-child pair, was reported the % of S. mutans genotypes isolated from the children.
|
Three months after the birth of the child.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 janvier 2015
Achèvement primaire (Réel)
1 octobre 2017
Achèvement de l'étude (Réel)
1 décembre 2017
Dates d'inscription aux études
Première soumission
14 avril 2021
Première soumission répondant aux critères de contrôle qualité
27 avril 2021
Première publication (Réel)
3 mai 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
3 mai 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
27 avril 2021
Dernière vérification
1 avril 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Oral health promotion
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Oui
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Oui
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .